Prostate Cancer News and Research

Latest Prostate Cancer News and Research

BRCA2 carriers more likely to develop aggressive and lethal prostate cancer

Carriers of a BRCA2 variation specific to Iceland are more likely to develop aggressive and lethal prostate cancer than noncarriers, according to a study published online in the Journal of the National Cancer Institute.

14 Jun 2007

New contributor to aggressive cancers

Mutations in the cell adhesion molecule known as integrin alpha 7 (integrin 7) lead to unchecked tumor cell proliferation and a significantly higher incidence in cancer spread, or metastasis, in several cancer cell lines, report researchers at the University of Pittsburgh School of Medicine in a study published in the Journal of the National Cancer Institute.

8 Jun 2007

African-American men understimate risk of prostate cancer

Many African-American men radically underestimate the likelihood that having a needle biopsy for suspected prostate cancer will result in a cancer diagnosis, according to a study from the University of Chicago Medical Center.

5 Jun 2007

Circulating tumor cells predict how prostate cancer patients do with chemotherapy

The number of tumor cells circulating in the bloodstream of patients with metastatic, hormone-resistant, prostate cancer can predict how they will do with chemotherapy, according to results of an international trial.

5 Jun 2007

Treatment for early prostate cancer associated with type of specialist seen

A new study analyzing men with localized prostate cancer shows that the specialty of the physician they see can influence the type of therapy they ultimately receive.

5 Jun 2007

Bone-targeting radioisotope radium-223 for prostate cancer treatment

The bone-targeting radioisotope radium-223 has delivered promising results in a randomised trial to test its efficacy in treatment of hormone-refractory prostate cancer (HRPC).

5 Jun 2007

Findings from study of immunotherapy vaccine in prostate cancer patients

Data from an ongoing study designed to explore the biologic and clinical activity of cancer immunotherapy sipuleucel-T, or Provenge, in patients with early stage recurrent prostate cancer who have a rising serum prostate specific antigen (PSA) level, but who have not yet developed metastatic disease will be presented by Oregon Health & Science University Cancer Institute researchers.

5 Jun 2007

Gabapentin reduces hot flashes in men receiving androgen deprivation therapy

North Central Cancer Treatment Group ( http://ncctg/ ) researchers based at Mayo Clinic ( http://www.mayo.edu/ ) in Rochester, Minn., have discovered that low doses of a drug used to prevent epileptic seizures and to treat nerve pain caused by shingles substantially reduces hot flashes in patients who are undergoing anti-hormonal treatment, or androgen-deprivation therapy, for prostate cancer.

5 Jun 2007

Gene therapy delivery of nerve growth factors reverses erectile dysfunction in mice

Rats with erectile dysfunction, or ED, that were injected with a gene therapy vector containing either of two nerve growth factors were able to regain normal function after four weeks, according to a study conducted by University of Pittsburgh School of Medicine researchers.

5 Jun 2007

Flaxseed halts prostate tumor growth

Flaxseed, an edible seed that is rich in omega 3-fatty acids and fiber-related compounds known as lignans, is effective in halting prostate tumor growth, according to a study led by Duke University Medical Center researchers.

5 Jun 2007

Shark fin no benefit to cancer victims

In the latest research into the benefits of alternative therapies for cancer, shark cartilage did not help patients with lung cancer live longer but ginseng and flaxseed appeared to offer some benefit to cancer patients.

3 Jun 2007

C-reactive protein identified as marker for prostate cancer survival

Oregon Health & Science University Cancer Institute researchers have identified a protein that is a strong indicator of survival for men with advanced prostate cancer.

3 Jun 2007

New class of compounds shows promise for cancer treatment

A new class of compounds developed by two University of Kentucky researchers shows promise as a nontoxic treatment of some cancers previously treated with toxic chemotherapy, the researchers report.

30 May 2007

High pretreatment PSA velocity predicts worse outcome

The most significant single predictor of aggressive prostate cancer is an elevated rate of increase in prostate specific antigen (PSA) levels, according to a new study.

28 May 2007

Long-term ulcerative colitis study shows Remicade responders maintained improvement

Findings presented at Digestive Disease Week 2007 (DDW), from long-term extensions of the ACT trials (Active Ulcerative Colitis 1 & 2) show that subjects with moderately to severely active ulcerative colitis (UC) who had responded to REMICADE (infliximab) in the blinded phase of the trials maintained improvement in their clinical symptoms for up to two years.

24 May 2007

Vitamin C, E and folate supplements don't protect against lung cancer

A study of more than 75,000 adults found that taking supplemental multivitamins, vitamin C and E and folate do not decrease the risk of lung cancer.

22 May 2007

Laparoscopic radical prostatectomy with robot technology can improve survival rate for prostate cancer patients

Performing less invasive laparoscopic surgery using robotic technology may improve survival rates for prostate cancer patients, according to a study by urologic oncologists at Thomas Jefferson University Hospital's multidisciplinary Genitourinary (GU) cancer center.

22 May 2007

Red wine protects men from prostate cancer

Researchers have found that men who drink an average of four to seven glasses of red wine per week are only 52% as likely to be diagnosed with prostate cancer as those who do not drink red wine, reports the June 2007 issue of Harvard Men's Health Watch .

22 May 2007

New breast cancer treatment may dispense with the need for chemotherapy

According to the latest research new hormone therapy drugs designed to treat breast cancer may dispense with the need for chemotherapy thus avoiding the nasty side effects associated with the treatment.

21 May 2007

Demand for VScan diagnostic test kits increases

Medical Services International Inc (Pink Sheets: MSITF) wishes to announce that as the mosquito season begins in different parts of the world; demand for the VScan diagnostic test kits that detect mosquito borne diseases is increasing. In particular, the demand is for VScan test kits that detect Malaria, Dengue Fever and West Nile.

18 May 2007